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Abstract
Introduction:Although noninferiority of cryoballoon ablation (CBA) and radiofrequency catheter
ablation for antral pulmonary vein isolation (APVI) has been reported in patients with paroxysmal
atrial fibrillation (PAF), it is not clear whether contact force sensing (CF-RFA) and CBA with the
second-generation catheter have similar procedural costs and long-term outcomes. The objective
of this study is to compare the long-term efficacy and cost implications of CBA and CF-RFA in
patients with PAF.
Methods and results:A first APVIwas performed in 146 consecutive patients (age: 63± 10 years,
men: 95 [65%], left atrial diameter: 42 ± 6 mm) with PAF using CBA (71) or CF-RFA (75). Clini-
cal outcomes and procedural costs were compared. The mean procedure time was significantly
shorter with CBA than with CF-RFA (98 ± 39 vs. 158 ± 47 minutes, P < 0.0001). Despite a higher
equipment cost in the CBA than the CF-RFA group, the total procedure cost was similar between
the twogroups (P=0.26), primarily drivenby a shorter procedureduration that resulted in a lower
anesthesia cost. At 25± 5months after a single ablation procedure, 51 patients (72%) in the CBA,
and55patients (73%) in theCF-RFAgroups remained free fromatrial arrhythmiaswithout antiar-
rhythmic drug therapy (P= 0.84).
Conclusions: The procedure duration was approximately 60 minutes shorter with CBA than CF-
RFA. The procedural costs were similar with both approaches. At 2 years after a single procedure,
CBA and CF-RFA have similar single-procedure efficacies of 72–73%.
K EYWORDS
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1 INTRODUCTION
Antral pulmonary vein isolation (APVI) is a common ablation strat-
egy in patients with paroxysmal atrial fibrillation (PAF). Although
prior studies have demonstrated the noninferiority of cryoballoon
ablation (CBA) compared to radiofrequency ablation (RFA) with
irrigated-tip catheters,1–3 limited data are available comparing the
procedural costs and long-term outcomes of APVI using exclusively
the second-generation cryoballoon catheter versus an irrigated-tip
force-sensing radiofrequency (RF) catheter. The purpose of this study
was to compare the costs and long-term outcomes of APVI of CBA
using the second-generation cryoballoon catheter and a contact
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TABLE 1 Patient characteristics
Variables CBA (n= 71) CF-RFA (n= 75) P
Age (years) 63± 10 (20–81) 62± 9 (39–80) 0.65
Male 53 (75) 42 (56) 0.02
Bodymass index (kg/m2) 31± 6 (19–46) 30± 5 (20–45) 0.71
AF history (months) 46± 33 (5–172) 52± 44 (6–204) 0.58
Left atrial diameter (mm) 42± 6 (29–55) 42± 6 (26–61) 0.99
Left ventricular ejection fraction 0.59± 0.06 (0.30–0.70) 0.60± 0.05 (0.45–0.70) 0.26
Hypertension 40 (56) 47 (63) 0.44
Structural heart disease 12 (17) 7 (9) 0.17
Coronary artery disease 10 (14) 5 (6)
Nonischemic cardiomyopathy 0 1 (1)
Hypertrophic cardiomyopathy 1 (1) 1 (1)
Atrial septal defect 1 (1) 0
Antiarrhythmic drugs 32 (45) 43 (57) 0.14
Beta-blockers 40 (56) 38 (51) 0.49
Calcium channel blockers 21 (30) 25 (33) 0.63
Warfarin 14 (20) 20 (27) 0.23
Novel oral anticoagulants 55 (77) 55 (73)
Aspirin 2 (3) 0
CHADS2 score 0.9± 0.8 (0–3) 0.8± 0.7 (0–4) 0.23
CHA2DS2-VASc score 1.3± 1.1 (0–4) 1.3± 0.9 (0–5) 0.99
Prior cavotricuspid isthmus ablation 3 (4) 7 (9) 0.33
Data are shown asmean± 1 standard deviation. Percent values are shown in parentheses.
force-sensing irrigated-tip ablation catheter (CF-RFA) in patients with
PAF.
2 METHODS
2.1 Study subjects
The subjects of this studywere 146 consecutive patientswithPAFwho
underwent catheter ablationof atrial fibrillation (AF). Patientswhohad
a prior ablation procedure were excluded from this study. There were
95 men and 51 women, and the mean age of the patients was 63 ± 10
years (Table 1). The mean left ventricular ejection fraction was 0.60 ±
0.06 and themean left atrial diameterwas42±6mm.The clinical char-
acteristics of the patients were similar in the two groups except for a
higher proportion of men in the CF-RFA group.
2.2 Electrophysiologic study and ablation
The study protocol was approved by the institutional review board
of the University of Michigan. All patients provided informed written
consent. Antiarrhythmic drug therapy was discontinued ≥5 half-lives
before the electrophysiological study, except for amiodarone, which
was discontinued >8 weeks before the procedure. Computed tomog-
raphy or magnetic resonance imaging was not systematically obtained
prior to RFA. The choice of CBA versus CF-RFA was based on oper-
ator preference. In patients taking warfarin with a target interna-
tional normalized ratio of 2–3, warfarin was continued. In patients
receiving one of the novel oral anticoagulants, the last dose of the
drug prior to the procedure was held and resumed 4 hours after
hemostasis was achieved. The catheter ablation procedure was per-
formed in the fasting state under monitored anesthesia care. Vascular
access was obtained through the femoral veins. A decapolar catheter
(E-Z Steer CS Decapolar, Biosense Webster, Inc., Diamond Bar, CA,
USA) was positioned in the coronary sinus. Transseptal catheteriza-
tion was performed under intracardiac echocardiography guidance. In
all patients, systemic anticoagulation was achieved with unfraction-
ated heparin to maintain the activated clotting time between 300 and
350 seconds throughout the procedure. Bipolar electrograms were
displayed and recorded at filter settings of 30 to 500 Hz (EPMed Sys-
tems, West Berlin, NJ, USA). Esophageal temperature was monitored
with an orogastric temperature probe (Level 1 R©, Smith Medical, Inc.,
Dublin, OH, USA). APVI was performed to isolate all pulmonary veins
(PVs). Cavotricuspid isthmus (CTI) ablation was performed in patients
who had clinical or inducible CTI-dependent atrial flutter. After APVI,
isoproterenol was infused up to 20 𝜇g/minute at the discretion of the
operator.
2.3 Second-generation CBA
After the transseptal puncture, an 8.5 F sheath (SL0TM, St. Jude Medi-
cal, Inc., St. Paul, MN, USA) was exchanged for a 15-F steerable sheath
(FlexCath R© , Medtronic, Inc., Minneapolis, MN, USA). A 28-mm Arc-
tic Front Advance R© cardiac cryoablation catheter was inserted into
the left atrium over a spiral mapping catheter (Achieve R© , Medtronic,
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Inc.). A 3-dimensional electroanatomical mapping system was used
to delineate PV anatomy and facilitate catheter navigation (EnSiteTM
VelocityTM, St. JudeMedical, Inc.). Complete PV antrum occlusion was
verified by radiocontrast injection. The freeze cycle duration was 3
minutes in all patients except in 4 patients who had 4-minute appli-
cations early in the study. To prevent phrenic nerve palsy during CBA
of the right-sided PVs, the right phrenic nerve was stimulated with a
decapolar catheter positioned in the superior vena cava. Phrenic nerve
capture was confirmed by monitoring the diaphragmatic contraction,
diaphragmatic compoundmotor action potentials recorded froma sur-
face electrocardiogram lead positioned over the right diaphragm, and
intermittent fluoroscopy. In case of attenuation or loss of diaphrag-
matic contraction, energy deliverywas discontinued immediately. If PV
isolation could not be achieved with CBA alone, CF-RFA was utilized.
The completeness of APVI was assessed by demonstrating entrance
and/or exit block in all PVs with a circular multielectrode catheter.
Procedural characteristics including the number of cryoapplications,
minimum inner balloon temperature, and the interval thaw time were
recorded. Interval thaw time was defined as the time needed for the
balloon to reach 0 ◦C after termination of cryoapplication.4
2.4 Contact force (CF) guided RF catheter ablation
Ablation was performed with a 3.5-mm open irrigated-tip CF sens-
ing catheter (ThermoCool R© , SmartTouchTM, Biosense Webster, Inc.)
with the guidance of an electroanatomical mapping system (CARTO R©
3, Biosense Webster, Inc.). PVs were mapped with a decapolar ring
catheter (LassoTM, Biosense Webster, Inc.). The average CF was
divided into four categories: low (>5 and <10 g), moderate (≥10
and< 15 g), high (≥15 and< 20 g), and very high (≥20 g).
RF energy was delivered at a maximum power of 20–25Watts with
a flow rate of 17 mL/minute near the PVs and along the posterior wall,
and at amaximumpower of 35Watts with a flow rate of 30mL/minute
elsewhere in the atria. Themaximum temperature was set at 48◦C.5,6
2.5 Procedure cost
The total procedure cost included the costs of equipment, anesthe-
sia services, and hospital care. Due to contractual obligations and to
account for the variability in pricing between centers, all cost data are
presented as the ratio of theCBA to theCF-RFAgroup, usingAPVI only
by CF-RFAwithout isoproterenol infusion as the base value.
2.6 Follow-up
After the ablation procedure, patients were monitored overnight and
discharged home the next day. Patients were seen in an outpatient
clinic 3, 6, and 12 months after the procedure and every 12 months
thereafter. They were instructed to call a dedicated nurse when-
ever they experienced symptoms. A 30-day autotriggered event mon-
itor (Lifestar AF ExpressTM, Life Watch Inc., Buffalo Grove, IL, USA)
was routinely utilized at 8 ± 5 months after the ablation. A car-
diac implantable electronic device was already present in 6 patients.
The same antiarrhythmic regimen a patient was taking prior to the
procedure was continued for 8–12 weeks after the ablation. Recur-
rence was defined as any symptomatic or asymptomatic atrial tach-
yarrhythmia lasting>30 seconds after the 3-month blanking period.
2.7 Statistical analysis
In this retrospective analysis, continuous variables were expressed as
mean ± 1 standard deviation and were compared using the Student's
t-test. Sequential continuous variables were compared using one-way
analysis of variance with repeated measures. Post-hoc comparisons
weremadewith the Scheffe test. Categorical variableswere compared
using the Fisher's exact test. Linear regression analysis was performed
to determine the relationship between procedure duration and cost.
Kaplan–Meier analysis with the log-rank test was used to compare
time to recurrent atrial arrhythmias after CBA and CF-RFA. A P< 0.05
indicated statistical significance.
3 RESULTS
3.1 PV isolation
In the CBA group, all four major PVs except for 1 right inferior PV and
one anomalous left superior PV were isolated, including six left com-
mon and four right middle PVs. The mean number of cryoapplications
was2.1±0.7 for the left superior PVs, 2.1±0.8 for the left inferior PVs,
3.8 ± 1.2 for the left common PVs, 2.0 ± 0 right superior PVs, 2.0 ± 0.8
right inferior PVs, and 1.3 ± 0.5 for right middle PVs. The mean time
to PV isolationwas 39± 27 seconds. Additional focal applications with
RFA were used to isolate one right superior and two right inferior PVs
in three patients.
In the CF-RFA group, complete PV isolation was achieved in 74 of
75 patients (99%), 6 of whom had a left common PV. Themean CF dur-
ing APVI was 18.7 ± 2.9 g and the median CF was 17.1 g. The mean
proportion of CF values was 6 ± 8%, 32 ± 12%, 29 ± 8%, 34 ± 16% for
low,moderate, high, and very high, respectively. Complete PV isolation
was achievedmore quickly in the CBA group than in the CF-RFA group
(24± 5 vs. 41± 11minutes, P< 0.0001; Table 2).
3.2 Additional ablation after PV isolation
Prior to the first AF ablation, atrial arrhythmias other than AF were
clinically documented in 16 patients (21%) in the CF-RFA group and
7 patients (10%) in the CBA group (P = 0.06). All 16 patients in the
CF-RFA group and 6 patients in the CBA group had atrial flutter. One
patient in theCBA group had a focal right atrial tachycardia, whichwas
successfully ablated.
CTI ablation using CF-RFA was performed in 11 (15%) and in
24 patients (32%) in the CBA and the CF-RFA groups, respectively
(P=0.02, Table 2). AfterAPVI, isoproterenolwas infused in 10patients
(14%) in the CBA and in 59 patients (79%) in the CF-RFA groups, and
induced frequent premature atrial depolarizations (n = 1) or an atrial
tachycardia (AT) (n = 2) in the CF-RFA group and an AT in 1 patient
in the CBA group. All inducible arrhythmias were successfully ablated
YOKOKAWA ET AL. 287
TABLE 2 Procedural characteristics and clinical outcome
CBA (n= 71) CF-RFA (n= 75) P
PV isolation
Duration of ablation for PV isolation (minutes) 24± 5 41± 11 <0.0001
Isoproterenol infusion after PV isolation 10 (14) 59 (79) <0.0001
Additional ablation
Cavotricuspid isthmus ablation 11 (15) 24 (32) 0.02
Inducible atrial arrhythmias with isoproterenol 3 (4) 5 (7) 0.72
Procedure time
Procedure duration after the transseptal puncture (minutes) 98± 39 158± 47 <0.0001
Procedure start-to-procedure end (minutes) 148± 41 207± 58 <0.0001
Anesthesia time (minutes) 204± 43 260± 62 <0.0001
Total fluoroscopy time (minutes) 30± 12 24± 10 <0.01
Periprocedural complications 1 (1) 3 (4) 0.62
Cardiac tamponade 0 2 (3)
Phrenic nerve palsy 1 (1) 0
Femoral arteriovenous fistula 0 1 (1)
Sinus rhythm after a single procedure 51 (72) 55 (73) 0.84
Repeat ablation 14/20 (70) 13/20 (65) 0.74
Cryoballoon ablation 0/14 (0) 5/13 (38) 0.02
Data are shown asmean±1 standard deviation. Percent values are shown in parentheses.
usingCF-RFA. Two patients in each group had successful slowpathway
ablation using CF-RFA for inducible slow-fast atrioventricular nodal
reentrant tachycardia.
3.3 Procedure duration
The mean procedure time after the transseptal puncture was signif-
icantly shorter in the CBA than in the CF-RFA group (98 ± 39 vs.
158±47minutes, P<0.0001;Table2). Themean total proceduredura-
tionwas also significantly shorter in theCBA than in theCF-RFA group
(148± 41 vs. 207± 58minutes, P< 0.0001).
3.4 Procedure cost
The equipment cost per patient was significantly higher in the
CBA group than the CF-RFA group (1.57 ± 0.26 vs. 1.15 ± 0.27,
P < 0.0001; Table 3). Because RFA had to be used to perform the
CTI ablation, equipment cost significantly increased in the CBA group
(2.01 ± 0.15 vs. 1.48 ± 0.18, P < 0.0001). The equipment cost in
patients who had CTI ablation in the CF-RFA groups was not signifi-
cantly different (1.16± 0.17 vs. 1.15± 0.31, P= 0.86).
Anesthesia cost was significantly lower in the CBA than in the
CF-RFA group (0.96 ± 0.14 vs. 1.08 ± 0.16, P < 0.0001). There was
a direct correlation between the anesthesia cost and the procedure
duration in both CBA group (r = 0.79; P < 0.0001) and in the CF-
RFA group (r = 0.89; P < 0.0001). Hospital-associated costs also
were significantly lower in the CBA group than in the CF-RFA group
(1.12 ± 0.21 vs. 1.18 ± 0.13, P = 0.02). Total cost was similar in the 2
groups (1.14± 0.20 vs. 1.17± 0.13, P= 0.26).
Isoproterenol infusion was associated with a higher hospital-
associated cost both in the CBA, 1.32 ± 0.10 versus 1.03 ± 0.16
(P < 0.001), and in the CF-RFA groups, 1.19 ± 0.10 versus 1.00 ± 0.14,
(P< 0.0001), respectively. CTI ablation after APVIwas associatedwith
a significantly higher total cost in the CBA than in the CF-RFA group
(1.40 ± 0.12 vs. 1.22 ± 0.11, P < 0.0001; Table 3). The total procedu-
ral cost was similar among patients who underwent CBA and CF-RFA
without isoproterenol infusion and/or CTI ablation (Table 3).
3.5 Freedom from atrial arrhythmias after a single
ablation procedure
At 25 ± 5 months after a single ablation procedure, 51 patients (72%)
in the CBA group and 55 patients (73%) in the CF-RFA group remained
free from recurrent atrial arrhythmias without concomitant antiar-
rhythmic drug therapy (P = 0.84, Table 2). On Kaplan–Meier analysis,
freedom from atrial arrhythmias was similar in the CBA and CF-RFA
groups (log-rank P= 0.82, Fig. 1). Themechanism of recurrencewas an
AT in 2 of 20 patients (10%) in the CBA group and in 3 of 20 patients
(15%) in the CF-RFA group (P= 1.0). The probability of recurrencewas
similar among patientswhodid and did not have isoproterenol infusion
after APVI (18 of 69 [26%] vs. 22 of 77 [29%], P= 0.74).
3.6 Recurrences, CF, cryoballoon temperature
and thaw time
The number of cryo applications per PV was similar among patients
with and without recurrence (2.3 ± 1.0 vs. 1.9 ± 0.7, P = 0.29). The
minimum balloon temperature was significantly higher (−42 ± 8 vs.
−46 ± 6 ◦C, P < 0.01) and the interval thaw time was significantly
shorter (8.2± 4.0 vs. 10.3± 4.2 seconds, P= 0.03) in patientswith than
without recurrence.
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In the CF-RFA group, the mean CF during APVI was similar among
patients with and without recurrent atrial arrhythmias (19.3 ± 2.6 vs.
18.4 ± 3.0 g, P = 0.25). No significant difference was observed in
the mean proportion of CF values between patients with and without
recurrence.
3.7 Repeat ablation and cost
A repeat ablation procedurewas performed in 14 patients (20%) in the
CBA group and in 13 patients (17%) in the CF-RFA group (P = 0.71,
Table 2) 10 ± 6 months after the index procedure. During the repeat
ablation, CBA was used in 5 patients who underwent CF-RFA during
the first procedure. CF-RFA was used in the remaining 22 repeat abla-
tion procedures.
Recovery of conduction was observed in a mean of 2.4 ± 1.2 PVs
per patient in the CBA group, including four left superior PVs, five left
inferior PVs, three left common PVs, nine right superior PVs, and 10
right inferior PVs. In the CF-RFA group, a mean of 3.2 ± 1.1 PVs per
patient had recovery of conduction, including nine left superior, 11 left
inferior, seven right superior, and 11 right inferior PVs (P= 0.08). All of
the PVs were reconnected in 4 of 14 patients (29%) in the CBA group
and 7 of 13 patients (54%) in the CF-RFA group (P= 0.25).
The total repeat ablation cost of CF-RFAwas 1.18± 0.16 compared
to initial CF-RFA (P = 0.83). The total cost of CBA during repeat pro-
cedures was 1.17 ± 0.12 compared to the initial CBA (P = 0.74). The
total cost of first and repeat procedures was similar among patients
who underwent both CBA and CF-RFA (2.22 ± 0.24) or only CF-RFA
(2.36± 0.39, P= 0.26).
After a mean of 1.2 ± 0.4 procedures, and 24 ± 6 months after the
last procedure, 63 patients (89%) in the CBA group and 67 patients
(89%) in the CF-RFA group remained free from recurrence without
antiarrhythmic drugs (P = 0.91). The probability of remaining in sinus
rhythm was similar in patients who underwent only CBA (52 of 58
[90%]), only CF-RFA (62 of 70 [89%]) or both CBA and CF-RFA (16 of
18 [89%], P= 0.98).
3.8 Complications
There was no significant difference in the prevalence of perioperative
complications between the CBA and CF-RFA groups (1 of 71 [1%] vs.
3 of 75 [4%]; P = 0.62, Table 2). Pericardial tamponade occurred in 2
patients in the CF-RFA group, and was successfully treated with peri-
cardiocentesis including the patient who had perforation during abla-
tion in a recess along the CTI. In the other patient, the real-time CF
showed a transient increase in CF of 110.5 g (>100 g for 200 millisec-
onds) during APVI. A left-sided phrenic nerve paralysis was diagnosed
in a patient who presented with dyspnea 1week after CBA.
4 DISCUSSION
4.1 Major findings
The results of this study demonstrate that: (1) At 2 years of follow-
up after a repeat ablation in 20% of the patients, freedom from atrial
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F IGURE 1 Kaplan–Meier analysis showing the atrial tachyarrhythmia-free survival rate after a single ablation procedure. A blanking period of
3months was applied
arrhythmias was maintained in ∼90% of the patients in both groups
without antiarrhythmic drug therapy; (2) the overall procedure dura-
tion was approximately 60 minutes shorter with CBA than CF-RFA;
and (3) the total procedure cost was similar between the CBA and CF-
RFA groups, despite a higher catheter cost in the CBA group. This was
driven primarily by the lower anesthesia costs attributable to a shorter
procedure duration in the CBA group.
4.2 CBA versus CF-RFA
The most common cause of recurrence after an initially success-
ful ablation is recovery of conduction over the PV fascicles. CF-
sensing catheters have been introduced to improve the durability of
the lesions.7 Based on prior studies,8 an effort to maintain a CF >
10 g was made and almost always achieved by all operators. Nev-
ertheless, clinical efficacy was still similar to CBA, and recovery of
conduction was observed in a similar proportion of patients after
CBA or CF-RFA.1,2 The main difference between CBA and CF-RFA
for APVI was a shorter overall procedure time of approximately
60minutes.
4.3 Cost implications
CBA has a higher cost than the CF-RFA system. However, this increase
in the equipment cost was negated by a shorter procedure duration.
Procedure duration directly affects the time dependent cost elements
such anesthesia services, use of the electrophysiology laboratory, and
postanesthesia recovery units. Therefore a decrease in the procedure
duration directly reduces the anesthesia service costs and hospital-
associated costs.
Because it is likely that there are variations in operator preference,
and expertise with one technique than the other even within the same
institution, it is possible to model cost structures as described in this
study based on the relative procedural efficacy, and duration for an
operator and the cost of equipment, anesthesia, and hospital services
at a given center. This should allow a cost effective decision to bemade
by factoring in these critical variables.
Switching to CF-RFA after CBA for ablation of atrial flutter or other
arrhythmias is associated with a substantial increase in the total cost.
Therefore from a cost perspective, it may be preferable to start with
CF-RFAwhen the patient is known to have other arrhythmias, particu-
larly atrial flutter, prior to the procedure.
Although anesthesia services are routinely used during catheter
ablation of AF in most centers, ablation might be performed without
anesthesia staff based on the availability of resources at certain cen-
ters. Because anesthesia service is a major determinant of procedural
cost, the cost structure will have to be modeled differently for these
centers.
Isoproterenol is a costly drug and has been used to assess the
inducibility of residual arrhythmias. Isoproterenol was infrequently
used in the CBA group based on operator preference in this study.
However, overall clinical efficacy was similar among patients who
were and were not administered isoproterenol after PVI. It is pos-
sible that after wide antral PV isolation, there will be fewer resid-
ual antral foci. Nevertheless, isoproterenol may still be helpful to
identify both residual triggers and other arrhythmias in a small
subset of the patients in a larger study population. Therefore,
use of isoproterenol should be carefully determined by the oper-
ator considering the patient characteristics, likelihood of identify-
ing residual arrhythmias, alternative approaches, and potential cost
implications.
4.4 Prior studies
To our knowledge this is the first study that systematically com-
pared the costs of APVI by CBA and CF-RFA. In a registry from four
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centers, CBAwith a second-generation catheter andCF-RFAusing two
different catheter systems was compared in patients with PAF.1 Sin-
gle procedure efficacy was similar between the two groups. Although
procedure duration with CBA was shorter by only 13 minutes, fluo-
roscopy exposure was similar between the two groups. The recently
publishedmulticenter FIREand ICE trial that randomizedpatientswith
PAF to cryoballoon (378) versus RFA without CF sensing ability (384)
demonstrated noninferiority of CBA to RFA.3 However, there have
been improvements both in cryoballoon (second generation) and RF
catheters (CF sensing ability) since the start of this trial. In a recent
randomized trial, 237 patients with PAF were randomized to RFA ver-
sus CBA versus combined RFA and CBA.9 At 1 year of follow-up, 47%
in the RFA, 67% in the CBA, and 76% in the combined group were
free fromatrial arrhythmiaswithout antiarrhythmic drug therapy. CBA
was quicker, and both CBA and combined approaches were superior
to RFA. However, a first-generation cryoballoon was used and the RF
catheter did not have CF sensing capability. In a nonrandomized study,
150 patients with PAF underwent CBA with a second-generation cry-
oballoon and CF-RFA.2 However, operators were assigned to perform
only the type of ablation approachwithwhich they had extensive expe-
rience. The duration of the procedure was shorter in the CBA group.
AF recurrence rate, 12–15%, at 12 months was similar in both groups.
Lastly, a recent study demonstrated that the individualized cryoappli-
cations guidedby the time toPV isolationwereassociatedwithapprox-
imately 60 minutes shorter total procedure time as compared to the
conventional cryoablation strategy. This reduction in procedure dura-
tion may lower the anesthesia and hospital associated costs associ-
ated with CBA.10 However, a RFA catheter had to be used in 15% of
the patients, which may negate some of the cost reductions due to the
shorter procedure duration.
4.5 Limitations
The main limitation of this study is that the use of CF-RFA versus CBA
was not decided on a random basis but was based on operator discre-
tion.CTI ablationwasperformedmore frequently in theCF-RFAgroup.
It is likely that a history of atrial flutter may have prompted the choice
of CF-RFA. Another limitation is that all of the operators had many
moreyears of experiencewithRFA thanwithCBA,whichmayhave cre-
ated a bias in favor of RFA.
5 CONCLUSIONS
Both CBA and CF-RFA in patients with PAF have a similar procedu-
ral efficacy and safety. However, the CBA procedure is significantly
shorter than CF-RFA. Despite a higher equipment cost, CBA for APVI
appears tohavea similar total cost toCF-RFAprimarily drivenby lesser
anesthesia and hospital associated costs and infrequent use of isopro-
terenol.
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